This study aimed to assess the efficacy of preemptive TAF therapy in preventing clinically significant HBV reactivation in patients with “resolved” HBV infection (HBsAg-negative, anti–HBc-positive) receiving rituximab-based chemotherapy for lymphoma. The gene discussed is KRT88P; the disease is lymphoma.